(Q36893299)

English

Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy

scientific article published on 31 March 2013

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy (English)

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

multiple myeloma

1 reference

based on heuristic

inferred from title

Elisabeth G. Vichaya

object named as

Elisabeth G Vichaya

1

0 references

Patrick M. Dougherty

object named as

Patrick M Dougherty

10

0 references

Charles S Cleeland

9

object named as

Charles S Cleeland

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

author name string

Xin Shelley Wang

2

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Jessica A Boyette-Davis

3

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Tito R Mendoza

4

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Zijing He

5

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Sheeba K Thomas

6

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Nina Shah

7

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Loretta A Williams

8

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

publication date

31 March 2013

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

71

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

1531-1540

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Validation of the M. D. Anderson Symptom Inventory multiple myeloma module

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

29 September 2017

Neuropathic pain: is quantitative sensory testing helpful?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

29 September 2017

Subclinical peripheral neuropathy is a common finding in colorectal cancer patients prior to chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

29 September 2017

Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

29 September 2017

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

29 September 2017

Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

29 September 2017

Patient perceptions associated with chemotherapy-induced peripheral neuropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

29 September 2017

Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

29 September 2017

Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

29 September 2017

Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

29 September 2017

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

29 September 2017

Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

29 September 2017

Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

29 September 2017

Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

29 September 2017

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

29 September 2017

Neurological aspects of multiple myeloma and related disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

29 September 2017

Neurologic complications of plasma cell disorders

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

29 September 2017

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

29 September 2017

A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

29 September 2017

Response properties of mechanoreceptors and nociceptors in mouse glabrous skin: an in vivo study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

29 September 2017

Evidence for two different heat transduction mechanisms in nociceptive primary afferents innervating monkey skin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

29 September 2017

Evaluation of pre-existing neuropathy and bortezomib retreatment as risk factors to develop severe neuropathy in a mouse model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

27 June 2018

Genetic variation associated with bortezomib-induced peripheral neuropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

27 June 2018

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

27 June 2018

Test-retest and interobserver reliability of quantitative sensory testing according to the protocol of the German Research Network on Neuropathic Pain (DFNS): a multi-centre study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

4 September 2018

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

4 September 2018

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

4 September 2018

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

4 September 2018

Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

4 September 2018

Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

4 September 2018

Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

4 September 2018

Thalidomide-induced neuropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

4 September 2018

Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3669643

4 September 2018

Asking the Community About Cutpoints Used to Describe Mild, Moderate, and Severe Pain

1 reference

https://pubmed.ncbi.nlm.nih.gov/23543296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib

1 reference

https://pubmed.ncbi.nlm.nih.gov/23543296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23543296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23543296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dysfunction in Multiple Primary Afferent Fiber Subtypes Revealed By Quantitative Sensory Testing in Patients with Chronic Vincristine-Induced Pain

1 reference

https://pubmed.ncbi.nlm.nih.gov/23543296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quantitative Sensory Findings in Patients With Bortezomib-Induced Pain

1 reference

https://pubmed.ncbi.nlm.nih.gov/23543296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reliability and validity of quantitative sensory testing in persons with spinal cord injury and neuropathic pain

1 reference

https://pubmed.ncbi.nlm.nih.gov/23543296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m

1 reference

https://pubmed.ncbi.nlm.nih.gov/23543296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Secondary hyperalgesia persists in capsaicin desensitized skin

1 reference

https://pubmed.ncbi.nlm.nih.gov/23543296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gender- and age-specific changes in motor speed and eye-hand coordination in adults: normative values for the Finger Tapping and Grooved Pegboard Tests

1 reference

https://pubmed.ncbi.nlm.nih.gov/23543296

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00280-013-2152-7

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36893299&oldid=2199513687"